Blood clots should be listed as a “very rare” side effect of the Johnson & Johnson coronavirus vaccine but its benefits still outweigh the risks, the EU’s drug watchdog said on Tuesday.
The European Medicines Agency (EMA) said in a statement that it had found a “possible link” between the jab and the clots, following eight such cases in the United States, one of which was fatal.
Concerns over the vaccine by US pharmaceutical giant Johnson & Johnson and the jab by rival drugmaker AstraZeneca have dampened hopes that vaccines could offer a swift end to the pandemic.
“EMA finds possible link to very rare cases of unusual blood clots with low blood platelets,” the Amsterdam-based agency said in a statement, adding that it “confirms (the) overall benefit-risk remains positive.”
The regulator said its safety committee “concluded that a warning about unusual blood clots with low blood platelets should be added to the product information” for the J&J shot.
Its experts also “concluded that these events should be listed as very rare side effects of the vaccine.”
“The cases reviewed were very similar to the cases that occurred with the COVID-19 vaccine developed by AstraZeneca, Vaxzevria,” the EMA statement said.
The eight cases in the US, out of some seven million people who had received the vaccine, all involved people under the age of 60, the majority of whom were women, it said.
“Based on the currently available evidence, specific risk factors have not been confirmed,” the EMA said.
EMA chief Emer Cooke was due to hold a press conference on the decision at 1500 GMT.
Johnson & Johnson last week delayed the rollout of its single-shot jab across Europe pending the result of the EMA probe.
J&J said earlier Tuesday that it was “very confident” in its vaccine and hopeful for a quick resolution from regulators over its status.
The EU approved the Johnson & Johnson shot on March 11 and started taking delivery of the vaccine on April 19.
But with concerns already mounting over clots linked to AstraZeneca, the EMA announced on April 9 that it was also probing cases connected to the J&J vaccine.
US regulators have suspended the Johnson & Johnson vaccine and is set to announce its decision on Friday.
Both the Johnson & Johnson and AstraZeneca vaccines use the same adenovirus vector technology.
They use a common-cold causing adenovirus, modified so it cannot replicate, as a “vector” to shuttle genetic instructions into human cells, telling them to create a protein of the coronavirus, and training them to be ready for live COVID.
AstraZeneca opted for a chimpanzee adenovirus, J&J for a human adenovirus.
Other COVID adenovirus vector vaccines include Russia’s Sputnik V and China’s CanSino.
Many European countries have continued to restrict the use of AstraZeneca, despite the EMA declaring it safe and saying blood clots are only a “very rare” side effect.
Follow the latest news on the coronavirus (COVID-19) outbreak
© 2021 AFP
EMA links Johnson & Johnson vaccine to blood clots (2021, April 20)
retrieved 20 April 2021
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
- WHO’s technical advisory group to meet on Oct 26 to consider Covaxin - October 19, 2021
- 163 oxygen plants set up in MP after shortage during 2nd COVID-19 wave: CM Shivraj Singh Chouhan - October 19, 2021
- India’s R-value below 1 since September, researchers say - October 19, 2021
- Mumbai: Double vaccine jab not mandatory to enter theatres, colleges to reopen with 50% attendance - October 19, 2021
- Daily exercise routine, balanced diet, active lifestyle & quality sleep key to success in personal & professional lives: Experts - October 19, 2021
- Storia® Food & Beverages gets backed by Sixth Sense Ventures - October 19, 2021
- No COVID-19 death in Mumbai for first time almost since pandemic began - October 18, 2021
- New govt hospital to come up in Delhi’s Shalimar Bagh - October 18, 2021
- Mix-and-match vaccines highly effective against COVID-19: Lancet - October 18, 2021
- Self-reliance: Govt aims to make semiconductors in India by mid-2022 - October 18, 2021